---
schema_version: "secwatch.filing_event.v1"
accession: "0001178913-26-004178"
form_type: "8-K"
ticker: "ENTXW"
cik: "0001638097"
company_name: "Entera Bio Ltd."
filed_at: "2026-08-18T12:00:59+00:00"
generated_at: "2026-08-18T12:05:11.007316+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Entera Bio appoints Riccardo Paolo Camisasca as CMO ahead of EB613 Phase 3

## Summary
- Dr. Riccardo Paolo Camisasca appointed Chief Medical Officer effective Aug 18, 2026.
- He brings 30+ years experience; most recently Global Head of R&D at Sumitomo Pharma Switzerland.
- Appointment strengthens clinical team ahead of planned EB613 Phase 3 initiation for osteoporosis.
- Previously led R&D integration across Urovant, Enzyvant, Altavant, and Myovant at Sumitomo.
- CEO Miranda Toledano cites his rare combination of developing drugs across global R&D organizations.

## SEC filing metadata
- accession: 0001178913-26-004178
- form_type: 8-K
- ticker: ENTXW
- cik: 0001638097
- company_name: Entera Bio Ltd.
- filed_at: 2026-08-18T12:00:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1638097/000117891326004178/0001178913-26-004178-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1638097/000117891326004178/zk2635983.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001178913-26-004178
- JSON: https://secwatch.observer/filing/0001178913-26-004178.json
- Plain text: https://secwatch.observer/filing/0001178913-26-004178.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.